Home > Products > Antibodies > Biosimilars

Research Grade Lebrikizumab (HW632026)

Price(USD): $
Spec:
  • 100ug
  • 1mg
Number:
Contact us
  • Overview
  • Images
  • References
  • Datasheet
Overview
Catalog No.HW632026
Species reactivityHuman
ApplicationsResearch Grade Biosimilar
Host speciesHumanized
IsotypeIgG4-kappa
Expression systemMammalian Cells
SpeciesHuman
ClonalityMonoclonal
TargetIL13, NC30, Interleukin-13, IL-13
Endotoxin levelPlease contact with the lab for this information.
Purity>95% as determined by SDS-PAGE.
PurificationProtein A/G purified from cell culture supernatant.
AccessionP35225
FormLiquid
Storage buffer0.01M PBS, pH 7.4.
Stability and StorageUse a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternate NamesMILR1444A, PRO301444, CAS: 953400-68-5
BackgroundLebrikizumab (TNX-650) is an IgG4 humanized anti-interleukin-13 (IL-13) mAb with anti-itch effects that specifically binds to IL-13 in a non-receptor binding domain and inhibits its function. Lebrikizumab inhibits the IL-13 driven Th2 inflammatory response and blocks the signaling of IL-4Rα/IL-13Rα1. Lebrikizumab can be used for the research of asthma, atopic dermatitis and neuroinflammatory diseases.
NoteFor research use only. Not suitable for clinical or therapeutic use.
Images
  • Bioactivity

    Detects Human IL13 in indirect ELISAs.

References

Recommendation